Keryx reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh reiterated Keryx Biopharmaceuticals, Inc. at a buy. The analyst believes the recent addition of UCN-01 to the company's pipeline may prove promising. UCN-01 demonstrated activity in a range of tumor types and could be used in combination with Keryx's perifosine, according to Walsh. Shares of the New York City-based development-stage company were up 53 cents, or 4.39%, at $12.60. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.